Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema
AiViva Biopharma completed enrollment and dosing in a phase 1 trial of AIV007, a tyrosine kinase inhibitor for wet AMD and DME, administered via periocular injection. The trial, involving 18 participants, aims to evaluate safety over 6 months, with full results expected in Q1 2025.
Reference News
Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema
AiViva Biopharma completed enrollment and dosing in a phase 1 trial of AIV007, a tyrosine kinase inhibitor for wet AMD and DME, administered via periocular injection. The trial, involving 18 participants, aims to evaluate safety over 6 months, with full results expected in Q1 2025.